Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other financing activities: 2010-2022

Historic Other financing activities for Myriad Genetics (MYGN) over the last 7 years, with Sep 2022 value amounting to $700,000.

  • Myriad Genetics' Other financing activities was N/A to $700,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is 142.86% up from last year.
  • As of Q3 2022, Myriad Genetics' Other financing activities stood at $700,000, which was down 41.67% from $1.2 million recorded in Q1 2021.
  • Myriad Genetics' 5-year Other financing activities high stood at $129.6 million for Q2 2019, and its period low was -$500,000 during Q3 2019.
  • In the last 3 years, Myriad Genetics' Other financing activities had a median value of $1.0 million in 2020 and averaged $975,000.
  • Data for Myriad Genetics' Other financing activities shows a peak YoY increase of 850.00% (in 2019) and a maximum YoY decrease of 126.32% (in 2019) over the last 5 years.
  • Over the past 5 years, Myriad Genetics' Other financing activities (Quarterly) stood at $2.6 million in 2018, then slumped by 30.77% to $1.8 million in 2019, then skyrocketed by 300.00% to $1.0 million in 2020, then reached $1.2 million in 2021, then reached $700,000 in 2022.
  • Its last three reported values are $700,000 in Q3 2022, $1.2 million for Q1 2021, and $1.0 million during Q3 2020.